The estimated Net Worth of Ben Gil Price is at least $585 millier dollars as of 29 January 2019. Dr Price owns over 15,000 units of NeuroBo Pharmaceuticals Inc stock worth over $56,250 and over the last 12 years he sold NRBO stock worth over $0. In addition, he makes $529,232 as CEO & Pres at NeuroBo Pharmaceuticals Inc.
Dr has made over 4 trades of the NeuroBo Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of NRBO stock worth $9,150 on 29 January 2019.
The largest trade he's ever made was buying 15,000 units of NeuroBo Pharmaceuticals Inc stock on 29 January 2019 worth over $9,150. On average, Dr trades about 1,885 units every 153 days since 2012. As of 29 January 2019 he still owns at least 15,000 units of NeuroBo Pharmaceuticals Inc stock.
You can see the complete history of Dr Price stock trades at the bottom of the page.
Dr. Ben Gil Price M.D. is the CEO & Pres at NeuroBo Pharmaceuticals Inc.
As the CEO & Pres of NeuroBo Pharmaceuticals Inc, the total compensation of Dr D at NeuroBo Pharmaceuticals Inc is $529,232. There are no executives at NeuroBo Pharmaceuticals Inc getting paid more.
Dr D is 65, he's been the CEO & Pres of NeuroBo Pharmaceuticals Inc since . There are 1 older and 10 younger executives at NeuroBo Pharmaceuticals Inc. The oldest executive at NeuroBo Pharmaceuticals Inc is Michael Salsbury, 70, who is the Independent Director.
Ben's mailing address filed with the SEC is C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY STREET, OFFICE 19TH FLOOR, BOSTON, MA, 02116.
Over the last 5 years, insiders at NeuroBo Pharmaceuticals Inc have traded over $0 worth of NeuroBo Pharmaceuticals Inc stock and bought 2,544,530 units worth $7,964,379 . The most active insiders traders include St Co., Ltd Dong A, Tae Heum Jeong et Steven R. Ph.D. Gullans. On average, NeuroBo Pharmaceuticals Inc executives and independent directors trade stock every 0 days with the average trade being worth of $9,541,988. The most recent stock trade was executed by St Co., Ltd Dong A on 23 June 2024, trading 2,544,530 units of NRBO stock currently worth $7,964,379.
neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.
NeuroBo Pharmaceuticals Inc executives and other stock owners filed with the SEC include: